Tau PET Imaging for Primary Progressive Aphasia
Start: February 2016
End: February 1, 2024
Enrollment: 70
What Is This Study About?
Primary progressive aphasia (PPA) is a type of dementia that involves changes in the ability to use language to speak, read, write, and understand what others are saying. New tools are needed to help diagnose PPA. This study will test the effectiveness of the radioactive tracer, 18F-AV-1451, to detect the amount and location of tau, a protein that accumulates abnormally in the brains of people diagnosed with PPA. All participants will receive an injection of the tracer and then a positron emission tomography (PET) scan. The researchers will review the brain scans for the identification of tau patterns and monitor participants for any side effects.
Do I Qualify To Participate in This Study?
Minimum Age: 20 Years
Maximum Age: 100 Years
Must have:
- Diagnosis of PPA
Must NOT have:
- Pregnancy or potential for pregnancy
- Breastfeeding
- Receiving radiation treatment for a medical condition
If I Qualify, Who Do I Contact?
Contact study personnel listed either under the general study contact or the location nearest you.
Need Help?
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
| Illinois | |
|---|---|
|
Cognitive Neurology and Alzheimer's Disease Center - Northwestern University
Chicago, IL 60611
Recruiting
Seyi Adeolu |
|
Who Sponsors This Study?
Lead: Northwestern University
Collaborator Sponsor
- National Institute on Aging (NIA)
Source: ClinicalTrials.gov ID: NCT03283449